Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (387)
- Scheduling (national classification system) (168)
- Safety monitoring and information (28)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
768 result(s) found, displaying 451 to 475
-
Corporate reportsThis report describes the first 12 months of the mandatory reporting scheme
-
Corporate reportsThe TGA thanks respondents who provided a submission in response to the public consultation paper.
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 5 March 2020
-
Corporate reportsThe Health Products Regulation Group has published a new regulatory science strategy
-
Corporate reportsOur plan for how HPRG will maintain and build its regulatory science capability over the next 5 years
-
Scheduling decisions (final)Final decision in relation to risankizumab
-
Scheduling decisions (final)Recommendations for the scheduling of New Chemical Entities for inclusion in the Poisons Standard
-
TGA laboratory testing reportsThe TGA Laboratories has published a detailed report related to the testing of measles vaccines available in Australia
-
Corporate reportsThe TGA has finalised the outcomes of the Lower Risk Registered OTC Products Review Pilot Project
-
Corporate reportsTGA instructions for disinfectant testing.
-
Corporate reportsTargets have been met for most measures under the six KPIs
-
Corporate reportsRegulatory Impact Self-Assessment Report
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 27 November 2019
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 26 July 2019
-
Corporate reportsThe TGA has conducted a safety review on coumarin in topical listed medicines
-
Corporate reportsThe TGA thanks respondents who provided a submission in response to the public consultation paper.
-
Corporate reportsOn Monday, 2 December 2019, a TGA Progress Report to the Senate Mesh Inquiry was tabled in the Senate.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Scheduling decisions (final)Delegate-only final decision and reason for New Chemical Entities (NCE) - 1 December 2019 implementation date
-
Scheduling decisions (final)Final decisions to amend the Poisons Standard for substances referred to ACMS #27, ACCS #25, Joint ACMS-ACCS #22 (June 2019) and delegate-only decisions.
-
Corporate reportsFurther comments received on the consultation
-
Meeting statementsCommunique from the fourth meeting of the TGACC
-
Corporate reportsWe thank respondents who provided a submission in response to the public consultation paper, regulation of software, including Software as a Medical Device (SaMD).